In a CNBC Pro exclusive interview from JPMorgan's Annual Healthcare Conference in San Francisco, Sage Therapeutics CEO Jeff Jonas shared his views on the recent sell-off in biotech stocks.
"I think investors are still pretty optimistic about the overall space and the pace of innovation in medicine," said Jonas, explaining that as companies continue to innovate, patients will benefit along with the companies developing those treatments.
Jonas, who's an M.D., also spoke about the various catalysts and products for Sage Therapeutics, particularly a drug that aims to treat severe seizures.
Can't see the video? Here's how to become a CNBC Pro subscriber.
